- Scientists have identified a set of markers in urine that could lead to a more accurate and less invasive test for prostate cancer.
- Current PSA blood tests often result in false positives and unnecessary biopsies.
- The new markers, including molecules like SPON2, AMACR, and TMEFF2, are more precise than PSA in detecting prostate cancer presence and severity, according to a new study.
- Researchers used AI and gene activity analysis to identify these markers from tumour samples and validated the findings with patient samples.
- This urine test could enable earlier diagnosis, better prognoses, and reduce unnecessary biopsies, pending further validation in larger populations.
IN FULL